Familiarize yourself with KADCYLA® (ado-trastuzumab emtansine) preparation and storage in HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information.
How KADCYLA® (ado-trastuzumab emtansine) is Thought to Work in EBC
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant
Genentech's Kadcyla Is the First Targeted Therapy to Show
Risk-based Approaches for Optimizing Treatment in HER2-Positive
KADCYLA 160 mg ( ADO-TRASTUZUMAB EMTANSINE ) IV INFUSION VIAL
PDF) The EMA review of trastuzumab emtansine (T-DM1) for the
KADCYLA® (ado-trastuzumab emtansine) in HER2+ Early Breast Cancer
Herceptin (Trastuzumab): Side Effects, Uses, Dosage, Interactions
PDF) Mechanisms of resistance to trastuzumab emtansine (T-DM1) in
Ado-trastuzumab emtansine (Kadcyla) Drug Information
